安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Clinical efficacy and mechanisms of biologics for chronic . . .
outcomes of biologic therapy versus endoscopic sinus surgery, and discuss therapies in development and future directions (J Allergy Clin Immunol 2025;155:1401-10 ) Key words: Chronic rhinosinusitis, nasal polyp, CRSwNP, CRSsNP, biologic, benralizumab, dupilumab, mepolizumab, omalizumab, tezepelumab Chronic rhinosinusitis (CRS) encompasses a
- AAAAI 2025: Twice-yearly novel biologic shows promise in . . .
AAAAI 2025: Twice-yearly novel biologic shows promise in chronic rhinosinusitis with nasal polyps March 5, 2025 Depemokimab, an anti-IL-5 biologic administered biannually, offers a promising new treatment option for patients with chronic rhinosinusitis with nasal polyps (CRSwNP), significantly reducing polyp size and nasal congestion while maintaining a favorable safety profile
- Tezspire for Nasal Polyps: A New Targeted Therapy on the . . .
June 17, 2025 Tezspire for Nasal Polyps: A New Targeted Therapy on the Horizon June 17, 2025 Anaphylm: The Needle-Free Epinephrine June 4, 2025 FDA Warning: Stopping Zyrtec or Xyzal May Cause Rebound Itching—What Allergy Patients Need to Know June 3, 2025 How the Palisades and Altadena Fires Are Affecting Your Sinuses, Lungs, and Long
- Efficacy and Safety of Biologics for Chronic Rhinosinusitis . . .
Dupilumab, omalizumab, mepolizumab, and benralizumab have demonstrated good efficacy and safety in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) in phase 3 randomised controlled trials (RCTs) With recent regulatory approvals, there has been a surge in real-w …
- Ultra-long-acting biological therapy for chronic . . . - The Lancet
Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a common and particularly severe subset of sinonasal inflammatory disease that is characterised by benign outgrowths of the inflamed mucosa The management framework of CRSwNP substantially shifted with the introduction of biological agents 1–3 These therapies, targeting the Th2 cell cytokine pathways, drove reductions in both systemic
|
|
|